Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Related Parties

Related Parties	3 Months Ended
Mar. 31, 2022
Related Parties
Related Parties	7Related Parties The Company uses Gendreau Consulting, LLC, a consulting firm (“Gendreau”), for drug development, clinical trial design, implementation and execution of contracted activities with the clinical research organization. Gendreau’s managing member became the Company’s Chief Medical Officer (“CMO”) effective January 1, 2021. The Company has and will continue to contract the services of the CMO’s spouse through the firm to perform certain activities in connection with the Company’s ongoing clinical trial in FM. During the three months ended March 31, 2022 and 2021, the Company paid Gendreau $85,548 and $64,446, respectively, and had accounts payable of $36,870 and $24,840 to Gendreau as of March 31, 2022 and December 31, 2021, respectively.

Related Parties

3 Months Ended

Mar. 31, 2022

7Related Parties

The Company uses Gendreau Consulting, LLC, a consulting firm (“Gendreau”), for drug development, clinical trial design, implementation and execution of contracted activities with the clinical research organization. Gendreau’s managing member became the Company’s Chief Medical Officer (“CMO”) effective January 1, 2021. The Company has and will continue to contract the services of the CMO’s spouse through the firm to perform certain activities in connection with the Company’s ongoing clinical trial in FM. During the three months ended March 31, 2022 and 2021, the Company paid Gendreau $85,548 and $64,446, respectively, and had accounts payable of $36,870 and $24,840 to Gendreau as of March 31, 2022 and December 31, 2021, respectively.